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Abstract: Prion diseases are neurodegenerative diseases that are characterized by the conversion of the
cellular prion protein PrP(c) to the pathogenic isoform PrP(sc). Several antibodies are known to interact
with the cellular prion protein and to inhibit this transition. An antibody Fab fragment, Fab POM1,
was produced that recognizes a structural motif of the C-terminal domain of mouse prion protein. To
study the mechanism by which Fab POM1 recognizes and binds the prion molecule, the complex between
Fab POM1 and the C-terminal domain of mouse prion (residues 120-232) was prepared and crystallized.
Crystals of this binary complex belonged to the monoclinic space group C2, with unit-cell parameters a
= 83.68, b = 106.9, c = 76.25 Å, ฀ = 95.6°.
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Prion diseases are neurodegenerative diseases that are characterized by the
conversion of the cellular prion protein PrPc to the pathogenic isoform PrPsc.
Several antibodies are known to interact with the cellular prion protein and to
inhibit this transition. An antibody Fab fragment, Fab POM1, was produced that
recognizes a structural motif of the C-terminal domain of mouse prion protein.
To study the mechanism by which Fab POM1 recognizes and binds the prion
molecule, the complex between Fab POM1 and the C-terminal domain of mouse
prion (residues 120–232) was prepared and crystallized. Crystals of this binary
complex belonged to the monoclinic space group C2, with unit-cell parameters
a = 83.68, b = 106.9, c = 76.25 Å,  = 95.6.
1. Introduction
Prion diseases, also known as transmissible spongiform encephalo-
pathies (TSEs), are a group of fatal progressive neurodegenerative
disorders including bovine spongiform encephalopathy (BSE) in
cattle, chronic wasting disease (CWD) in cervids, scrapie in sheep
and goats, and Creutzfeldt–Jakob disease (CJD) in humans (Aguzzi
& Polymenidou, 2004). Several other forms of human prion disease
are also known; these include kuru, variant Creutzfeldt–Jakob
disease (vCJD), Gerstmann–Straussler–Scheinker (GSS) disease and
fatal familial insomnia (FFI) (Collinge, 2001). These diseases are
associated with the conversion of normal cellular prion protein (PrPc)
to a pathogenic conformation (PrPsc) that possesses abnormal
physiochemical properties such as insolubility, protease resistance
and the propensity to polymerize into amyloid-like fibrils (Prusiner,
1991). According to the ‘protein-only’ hypothesis, TSE transmission
is mediated only by PrPsc itself; PrPsc acts as a template for its self-
propagation through recruiting PrPc molecules and the cycle con-
tinues, leading to the formation of amyloid fibrils. The hallmark of
prion diseases is the accumulation of amyloid fibrils in the brain that
are associated with neuronal degradation characterized by nerve-cell
loss and spongiosis.
To date, there is no treatment available for prion disease; however,
any interruption to the conversion of PrPc to PrPsc in neurons could
potentially delay disease progression or even cure the disease (White
et al., 2003). Targeting cell-surface PrPc through monoclonal anti-
bodies appears to be a novel therapeutic strategy that could reduce
PrPsc accumulation, presumably by disrupting the PrPc–PrPsc inter-
action (Antonyuk et al., 2009). Furthermore, PrPc is converted to
different conformations during prion propagation; thus, any molecule
that binds specifically to PrPc should stabilize the native fold, thereby
inhibiting changes in conformation and consequently prion propa-
gation. In several in vitro and in vivo studies antiprion monoclonal
antibodies have been shown to reduce the number of scrapie prions,
and the development of prion disease has also been found to be
delayed in the murine model after an inoculation of antiprion anti-
body (White et al., 2003; Féraudet et al., 2005). Here, we report the
crystallization of a complex between a Fab fragment of the antibody
POM1 (Polymenidou et al., 2008) and the C-terminal part of mouse
prion protein.
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2. Experimental procedure and results
2.1. Mouse prion expression and purification
The pET15b plasmid (Novagen) containing the C-terminal struc-
tured domain (residues 120–232) of the mouse prion gene was
transformed into Escherichia coli BL21 (DE3) Codon Plus (Strata-
gene) cells. The cells were grown at 310 K in rich medium containing
100 mg ml1 ampicillin and the protein [MoPrP(120–232)] was mainly
expressed in inclusion bodies. The inclusion bodies were sonicated
(4  30 s with 60 s intervals at 50% amplitude), pelleted by centri-
fugation and extensively washed. The inclusion bodies were then
incubated in a denaturing buffer consisting of 6 M guanidinium
hydrochloride, 10 mM Tris–HCl, 100 mM NaH2PO4, 5 mM imidazole
pH 8.0 for 1 h at room temperature with constant stirring. The
extracted denatured proteins were loaded onto an Ni–NTA agarose
column (Qiagen) at a flow rate of 1 ml min1 after the addition of
10 mM reduced glutathione. The MoPrP(120–232) protein was
refolded on the column by a gradient application of buffer A
(denaturing buffer) and buffer B (10 mM Tris–HCl, 100 mM
NaH2PO4, 5 mM imidazole, pH 8.0) as described by Yin et al. (2003).
MoPrP(120–232) was then eluted with 300 mM imidazole in buffer B
and exchanged with distilled water using Amicon Ultra centrifugal
filters (3 kDa molecular-weight cutoff, Millipore). The purity of the
protein was confirmed by SDS–PAGE and the concentration was
measured by the Bradford method (Bradford, 1976).
2.2. Fab production
The IgG1 POM1 hybridoma was prepared as described by Poly-
menidou et al. (2008). The hybridoma cell-culture supernatant was
loaded onto a protein G Sepharose column and the POM1 antibody
was eluted with 0.1 M glycine pH 2.8. For Fab production, the IgG1
POM1 (1 mg ml1) was digested with papain at a POM1:papain ratio
of 1:0.02(w:w) in 50 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA and
2 mM cysteine (Andrew & Titus, 2001). After 5 h incubation at 310 K
in a water bath, papain was inactivated by adding iodoacetamide to
a final concentration of 3 mM. The digest was then concentrated,
exchanged with protein A IgG-binding buffer and loaded onto a
Protein A Sepharose column (Pierce). The Fc fragment and the
undigested IgG1 POM1 were bound to the protein A column,
whereas the POM1 Fab fragments were collected in the flowthrough.
The Fab fractions were then assessed for homogeneity by Coomassie
Brilliant Blue staining after separation by SDS–PAGE (Fig. 1).
2.3. Protein preparation and crystallization
Fab POM1 and MoPrP(120–232) were mixed in an equimolar ratio
in order to form the protein complex and the complex was purified by
Superdex G-75 (GE Healthcare) size-exclusion chromatography in a
buffer solution consisting of 50 mM Tris pH 7.0, 100 mM NaCl and
1 mM NaN3. The purified protein complex was then concentrated to
10 mg ml1 for crystallization studies. Screening of crystallization
conditions for the Fab POM1–MoPrP(120–232) complex was carried
out using several commercial screening solutions from Hampton
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Figure 1
SDS–PAGE analysis of purified Fab POM1 and its complex with MoPrP(120–232).
Lane M, molecular-weight marker (kDa); lane 1, Fab POM1–MoPrP(120–232)
complex; lane 2, Fab POM1; lane 3, MoPrP(120–232).
Figure 2
Crystals of the complex between Fab POM1 and MoPrP(120–232) grown using the
sitting-drop vapour-diffusion procedure at room temperature.
Figure 3
A representative 1 oscillation image of data collected from a crystal of the
complex between Fab POM1 and MoPrP(120–232).
Research in 96-well Intelli-Plates (Hampton Research) set up by a
crystallization robot (Hydra-Plus-One, Robbins Scientific). Crystal-
lization trays were set up using the sitting-drop vapour-diffusion
method, in which 0.4 ml protein sample was mixed with an equal
volume of screening solution. An initial crystallization hit was found
in a saturating solution of 25% PEG 3350, 0.1 M Bis-Tris pH 6.5 and
0.2 M lithium sulfate (condition G3 of Hampton Research Index
screen). After several optimization steps, crystals of approximate
dimensions 0.6  0.1  0.1 mm were obtained after 7 d (Fig. 2).
3. Results and discussion
A complete X-ray diffraction data set was collected from a single
crystal of the Fab POM1–MoPrP(120–232) complex cryocooled in
liquid nitrogen using reservoir solution containing 20% glycerol as
a cryoprotectant (Fig. 3). The synchrotron data were indexed and
scaled with the HKL-2000 suite of programs (Otwinowski & Minor,
1997). Data-collection statistics are shown in Table 1. Diffraction data
were collected from the crystals of the Fab POM1–MoPrP(120–232)
complex on the 08ID-1 beamline, Canadian Macromolecular Crys-
tallography Facility using a 300 mm CCD detector.
The crystals diffracted to 2.3 Å resolution. The crystal was found
to belong to space group C2, with unit-cell parameters a = 83.68,
b = 106.9, c = 76.25 Å,  = 95.6. A total of 27 952 unique reflections
were measured with an average multiplicity of 5.3. The merged data
set was 95.2% complete to 2.3 Å resolution, with an Rmerge of 8% and
a mean I/(I) of 21 for all reflections and 4.2 for the highest reso-
lution shell. The calculated Matthews coefficient was 2.9 Å3 Da1,
indicating the presence of one protein complex in the asymmetric
unit with a solvent content of 57% (Matthews, 1968). Structure
solution and analysis are currently in progress.
The crystal structure of the Fab POM1–MoPrP(120–232) complex
will shed light on the molecular interactions present between the two
proteins. This structural information will be helpful in designing
therapeutic products against prion diseases.
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Table 1
Data-collection and structure-solution statistics.
Values in parentheses are for the highest resolution shell.
Crystal dimensions (mm) 0.6  0.1  0.1
Matthews coefficient VM (Å
3 Da1) 2.9
Solvent content (%) 57
Crystal system Monoclinic
Space group C2
Unit-cell parameters (Å, ) a = 83.68, b = 106.9, c = 76.25,
 =  = 90,  = 95.6
No. of molecules in unit cell 1
Wavelength (Å) 0.993
Temperature (K) 100
Resolution range (Å) 30.0–2.3 (2.38–2.30)
No. of unique reflections 27952
No. of observed reflections 148536












i IiðhklÞ, where hI(hkl)i is the mean
intensity for multiply recorded reflections.
